• news.cision.com/
  • Integrum AB/
  • Integrum is granted patent approval for its OPRA[TM] Implant System from the US Patent and Trade Organization

Integrum is granted patent approval for its OPRA[TM] Implant System from the US Patent and Trade Organization

Report this content

Mölndal, Sweden, October 11th, 2022 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has received a patent approval in the US describing components and design features of the OPRATM Implant System, including elements that were implemented in 2017 and later were granted a PMA approval in late 2020. The patent period extends until 2044.

Integrum develops the OPRATM Implant System, a revolutionary implant technology based on the company’s deep expertise and innovations in osseointegration, that help amputees regain normal mobility and quality of life.

The current patent includes claims covering the system as a whole, including the anchoring solution for attaching a prosthesis into the human body as well as the abutment and the abutment screw. These claims extend beyond transfemoral applications, which currently make up the majority of treatment cases, to include treatment in other types of long bone prosthetic applications, such as the upper arm or lower leg.

Further, the claims cover design features for the connection between the abutment and the fixture, allowing a pathway for communication of physical and biophysical signals between inside and outside of the human body. Such design aspects are of vital importance to, for example, the e-OPRATM Implant System – Integrum’s state-of-the-art mind-controlled robotic prosthesis.

The patent grants Integrum exclusivity to OPRATM Implant System ranging from October 11th ,2022, until 2044 and is of vital importance to the continued commercial success on the world’s largest medical technology market.

“We are encouraged by this further recognition of Integrum as an innovative leader developing state-of-the-art products within osseointegration. We are currently working ambitiously to implement OPRATM Implant System as the new standard of care in amputation treatment, and the new patent offers broad protection for a long time ahead”, comments Rickard Brånemark, CEO of Integrum.

For more information please contact:

Rickard Brånemark, CEO. +46 (0) 70 846 10 61, E-mail: rickard.branemark@integrum.se

Dennis Baecklund, CFO. +46 (0) 72 556 68 69, E-mail: dennis.baecklund@integrum.se

Certified Adviser

Erik Penser Bank is Certified Adviser and can be reached at +46 (0) 8-463 8000.

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990, osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations enjoy a dramatically improved quality of life. Thorough surgical experience gained over more than three decades, from more than 500 surgeries, in 14 countries, has led to the development of Integrum’s system for bone-anchored prostheses – a vastly superior alternative to the traditionally used socket prosthesis


Documents & Links